Superseded Local Coverage Determination (LCD)

Trigger Point Injections

L35010

Expand All | Collapse All

Superseded

To see the currently-in-effect version of this document, go to the section.

Contractor Information

LCD Information

Document Information

LCD ID
L35010
LCD Title
Trigger Point Injections
Proposed LCD in Comment Period
N/A
Source Proposed LCD
N/A
Original Effective Date
For services performed on or after 10/01/2015
Revision Effective Date
For services performed on or after 01/21/2020
Revision Ending Date
11/17/2021
Retirement Date
N/A
Notice Period Start Date
N/A
Notice Period End Date
N/A
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2020 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2020 American Dental Association. All rights reserved.

Copyright © 2013 - 2021, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@aha.org.

CMS National Coverage Policy

This LCD supplements but does not replace, modify or supersede existing Medicare applicable National Coverage Determinations (NCDs) or payment policy rules and regulations for trigger point injections. Federal statute and subsequent Medicare regulations regarding provision and payment for medical services are lengthy. They are not repeated in this LCD. Neither Medicare payment policy rules nor this LCD replace, modify or supersede applicable state statutes regarding medical practice or other health practice professions acts, definitions and/or scopes of practice. All providers who report services for Medicare payment must fully understand and follow all existing laws, regulations and rules for Medicare payment for trigger point injections and must properly submit only valid claims for them. Please review and understand them and apply the medical necessity provisions in the policy within the context of the manual rules. Relevant CMS manual instructions and policies may be found in the following Internet-Only Manuals (IOMs) published on the CMS Web site:

IOM Citations:

  • CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual
    • Chapter 1, Part 1, Section 30.3 Acupuncture 
    • Chapter 1, Part 2, Section 150.7 Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents
  • CMS IOM Publication 100-08, Medicare Program Integrity Manual,
    • Chapter 13, Section 13.5.4 Reasonable and Necessary Provision in an LCD

Social Security Act (Title XVIII) Standard References:

  • Title XVIII of the Social Security Act, Section 1862(a)(1)(A) states that no Medicare payment shall be made for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury.
  • Title XVIII of the Social Security Act, Section 1862(a)(7). This section excludes routine physical examinations.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.

History/Background and/or General Information

Trigger point injection is one of many modalities utilized in the management of chronic pain. Myofascial trigger points are self-sustaining hyperirritative foci that may occur in any skeletal muscle in response to strain produced by acute or chronic overload. These trigger points produce a referred pain pattern characteristic for that individual muscle. Each pattern becomes part of a single muscle myofascial pain syndrome (MPS) and each of these single muscle syndromes are responsive to appropriate treatment, which includes injection therapy. An injection is achieved with the insertion of a needle and the administration of agents, such as local anesthetics, steroids and/or local inflammatory drugs.

The diagnosis of trigger points requires a detailed history and thorough physical examination. The following clinical symptoms may be present when making the diagnosis:

  • History of onset of the painful condition and its presumed cause (e.g., injury or sprain)
  • Distribution pattern of pain consistent with the referral pattern of trigger points
  • Range of motion restriction
  • Muscular deconditioning in the affected area
  • Focal tenderness of a trigger point
  • Palpable taut band of muscle in which trigger point is located
  • Local taut response to snapping palpation
  • Reproduction of referred pain pattern upon stimulation of trigger point


The goal is to treat the cause of the pain and not just the symptom of pain.

Covered Indications

After myofascial pain syndrome (MPS) is established, trigger point injection may be considered medically reasonable and necessary:

  1. When noninvasive medical management is unsuccessful (e.g., analgesics, passive physical therapy, ultrasound, range of motion and active exercises).
  2. As a bridging therapy to relieve pain while other treatments are also initiated, such as medication or physical therapy; or as a single therapeutic maneuver. The logic behind such therapeutic decision making should be obvious in the medical record and available upon Contractor request.
  3. When joint movement is mechanically blocked as is the case of the coccygeus muscle.


 Limitations

  1. Medicare does not cover Prolotherapy. Its billing under the trigger point injection code is a misrepresentation of the actual service rendered.
  2. When a given site is injected, it will be considered one injection service, regardless of the number of injections administered.


For frequency limitations, please refer to the Utilization Guidelines section below.

Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this policy, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

The redetermination process may be utilized for consideration of services performed outside of the reasonable and necessary requirements in this LCD.

Summary of Evidence

N/A

Analysis of Evidence (Rationale for Determination)

N/A

General Information

Associated Information


Refer to the Local Coverage Article: Billing and Coding: Trigger Point Injections, A57751, for all coding information.

Documentation Requirements

  1. All documentation must be maintained in the patient’s medical record and available to the contractor upon request.
  2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service[s]). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.
  3. The medical record documentation must support the medical necessity of the services as stated in this policy.
  4. For the treatment of established trigger points, the patient’s medical record must have:
    • Documentation of the evaluation/process of arriving at the diagnosis of the trigger point in an individual muscle should be clearly documented in the patient’s medical record.
    • The reason for the trigger point injection, and whether it is being used as an initial or subsequent treatment for myofascial pain, as well as the appropriate diagnosis code should be documented.

Utilization Guidelines

In accordance with CMS Ruling 95-1 (V), utilization of these services should be consistent with locally acceptable standards of practice.

It is expected that trigger point injections would not usually be performed more often than three sessions in a three month period. If trigger point injections are performed more than three sessions in a three month period, the reason for repeated performance and the substances injected should be evident in the medical record and available to the Contractor upon request.

This contractor may request records when it is apparent that patients are requiring a significant number of injections to manage their pain.

Documentation in the medical record must support the medical necessity and frequency of the trigger point injection(s).

Sources of Information

Contractor is not responsible for the continued viability of websites listed.

Other Contractor Policies

Contractor Medical Directors

Original JH ICD-9 Source LCD L33648, Trigger Point Injections

Bibliography
  1. Borg-Stein J, Stein J. Trigger Points and Tender Points: One and the Same? Does Injection Treatment Help? Rheum Dis Clin North Am 1996 May;22(2):305-22.
  2. Ferrante FM, Kaufman AG, Dunbar SA et al. Sphenopalatine Ganglion Block For The Treatment Of Myofascial Pain Of The Head, Neck, and Shoulders: Reg Anesth Pain Med 1998 Jan-Feb;23(1):30-6.
  3. Hameroff SR, Crago BR, Blitt CD, et al. Comparison of Bupivacaine, Etidocaine, and Saline for Trigger-Point Therapy: Anesth Analg 1981 Oct;60(10):752-5.
  4. Hans SC, Harrison P. Myofascial Pain Syndrome and Trigger-Point Management. Reg Anesth 1997 Jan-Feb;22(1):89-101.
  5. Harden RN, Bruehl SP, Gass S, et al. Signs and Symptoms of the Myofascial Pain Syndrome; A National Survey of Pain Management Providers: Clin J Pain 2000 Mar;16(1):64-72.
  6. Hong CZ, Hsueh TC. Difference in Pain Relief after Trigger Point Injections in Myofascial Pain Patients with and Without Fibromyalgia: Arch Phys Med Rehabil 1996 Nov;77(11):1161-6.
  7. Hong CZ.; Lidocaine Injection Versus Dry Needling To Myofascial Trigger Point. The Importance of the Local Twitch Response: Am J Phys Med Rehabil 1994 Jul-Aug;73(4):256.63.
  8. Hopwood MB, Abram SE. Factors Associated With Failure Of Trigger Point Injections. Clin J Pain 1994 Sep;10(3):227-34
  9. Pongratz DE, Sievers M. Fibromyalgia-Symptom or Diagnosis: A Definition Of The Position. Scand J Rheumatol Suppl; 200;113:3-7.
  10. Sist T, Miner M, Lema M. Characteristics Of Postradical Neck Pain Syndrome: A Report Of 25 Cases. J Pain Symptom Manage 1999 Aug;18(2):95-102
  11. Wittenberg RH, Steffen R, Ludwig J.; Injection Treatment Of Non-Radicular Lumbalgia: Orthopade 1997 Jun; 26(6):544-52.
  12. Wolfe F, Simons DG, Fricton J, et al. The Fibromyalgia And Myofascial Pain Syndromes: A Preliminary Study Of Tender Points And Trigger Points In Persons With Fibromyalgia, Myofascial Pain Syndrome And No Disease: J Rheumatol 1992 Jun; 19(6):944-51.
  13. Wyant GM. Chronic Pain Syndromes and Their Treatment. II Trigger Points: Can Anaesth Soc J 1979 May; 26(3):216-9.

Revision History Information

Revision History DateRevision History NumberRevision History ExplanationReasons for Change
01/21/2020 R6

LCD revised and published on 07/23/2020 effective for dates of service on and after 01/21/2020 as a non-discretionary update to remove the first limitation from the ‘Limitations’ section that states 1. Acupuncture is not a covered service, even if provided for the treatment of an established trigger point. Use of acupuncture needles and/or the passage of electrical current through these needles is not covered (whether an acupuncturist or other provider renders the service). This revision is consistent with CMS direction as noted in CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 1, Section 30.3 Acupuncture.

  • Other (Revised in response to CMS direction)
11/21/2019 R5

LCD revised and published on 11/21/2019. Consistent with CMS Change Request 10901, the entire coding section has been removed from the LCD and placed into the related Billing and Coding Article, A57751. Language contained in the CMS manuals has been removed from the LCD and replaced with references to the manuals. All CPT codes and coding information within the text of the LCD has been placed in the Billing and Coding Article.

  • Other (CMS Change Request 10901)
10/01/2018 R4

LCD revised and published on 10/25/2018 effective for dates of service on and after 10/01/2018 to reflect the ICD-10-CM Annual Code Updates. The following ICD-10-CM code(s) have been deleted and therefore removed from Group 1 Codes of the LCD: M79.1. The following ICD-10-CM code(s) have been added to Group 1 Codes: M79.11, M79.12, M79.18.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; therefore, not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To ICD-10-CM Code Changes
03/08/2018 R3

LCD revised and published on 03/08/2018. Per LCD annual review, standard formatting revisions were made throughout LCD without a change in coverage content. Added hyperlinks to NCDs 30.3 and 150.7 under “Related National Coverage Documents” in the “Associated Documents” section.
 
At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; therefore, not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
01/01/2016 R2 LCD revised and published on 03/16/2017 to make an administrative update. No content changes made.
  • Other (Administrative Change, No Content Change)
01/01/2016 R1 LCD revised and published on 01/28/2016 effective for dates of service on and after 01/01/2016 to reflect the annual CPT/HCPCS code updates. For the following CPT/HCPCS code either the short description and/or the long description was changed. Depending on which description is used in this LCD, there may not be any change in how the code displays in the document: 20553. Also, in this LCD version, the CPT/HCPCS code descriptions were changed from long descriptions to short descriptions.
  • Revisions Due To CPT/HCPCS Code Changes

Associated Documents

Attachments
N/A
Related Local Coverage Documents
Articles
A57751 - Billing and Coding: Trigger Point Injections
Public Versions
Updated On Effective Dates Status
11/12/2021 11/18/2021 - N/A Currently in Effect View
07/17/2020 01/21/2020 - 11/17/2021 Superseded You are here
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A

Read the LCD Disclaimer